Xeljanz (tofacitinib) approved for treatment of ulcerative colitis
Posted: June 08, 2018
Categories: Industry news
Moderately to severely active ulcerative colitis can now be treated with tofacitinib following an expanded approval by the FDA.
This will provide a much-needed alternative therapy for a debilitating disease with limited treatment options. To find out about ulcerative colitis and how this medicine works please read the full FDA article.